Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Depreciation and Depletion (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed Depreciation and Depletion for 7 consecutive years, with $2.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Depreciation and Depletion rose 45.0% to $2.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $8.3 million, a 12.16% increase, with the full-year FY2025 number at $8.3 million, up 12.16% from a year prior.
  • Depreciation and Depletion was $2.9 million for Q4 2025 at Kymera Therapeutics, up from $2.1 million in the prior quarter.
  • In the past five years, Depreciation and Depletion ranged from a high of $2.9 million in Q4 2025 to a low of $500000.0 in Q1 2021.
  • A 5-year average of $1.3 million and a median of $900000.0 in 2023 define the central range for Depreciation and Depletion.
  • Peak YoY movement for Depreciation and Depletion: surged 379.66% in 2021, then tumbled 66.64% in 2022.
  • Kymera Therapeutics' Depreciation and Depletion stood at $2.4 million in 2021, then plummeted by 66.64% to $800000.0 in 2022, then increased by 12.5% to $900000.0 in 2023, then soared by 122.22% to $2.0 million in 2024, then skyrocketed by 45.0% to $2.9 million in 2025.
  • Per Business Quant, the three most recent readings for KYMR's Depreciation and Depletion are $2.9 million (Q4 2025), $2.1 million (Q3 2025), and $1.7 million (Q2 2025).